Latest

Tirzepatide

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

This shows a brain in a wine glass with a syringe above it. Behind is a strand of DNA.

Featured Neuroscience

·February 21, 2026·7 min read

Mounjaro’s Active Ingredient Slashes Alcohol Intake

From weight loss to sobriety. New research reveals how the active ingredient in Mounjaro "mutes" the brain's reward system to slash alcohol cravings.

Featured Neuroscience

·November 17, 2025·9 min read

How Mounjaro Alters Craving Circuits in the Brain

A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain. Using implanted electrodes in a patient with treatment-resistant obesity and loss of control eating, researchers observed that the drug initially shut down signaling in the nucleus accumbens.

Featured Neuroscience

·August 22, 2025·4 min read

How Zepbound Targets the Brain and Pancreas

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite. Using fluorescent probes called daLUXendins, researchers visualized drug binding to insulin-producing beta cells and other pancreatic cell types, as well as brain regions tied to hunger regulation.

Featured Neuroscience

·May 13, 2025·6 min read

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with participants losing an average of 20.2% of their body weight versus 13.7%. The study directly compared the two drugs at their highest doses in people with obesity but without diabetes.